Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Umbricht

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Autism and Developmental Disorders|April 13, 2020
Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional AnalysisMarta Del Valle Rubido, Eric Hollander, James T McCracken, et al.
JAMA Psychiatry|June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition TrialsRichard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 8, 2012
Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteersMeret Martin-Facklam, Flavia Pizzagalli, Yun Zhou, et al.
Frontiers in Psychiatry|August 15, 2020
Social Anxiety in Children and Adolescents With Autism Spectrum Disorders Contribute to Impairments in Social Communication and Social MotivationKellen Briot, François Jean, Ali Jouni, et al.
Science Translational Medicine|September 30, 2011
Translating glutamate: from pathophysiology to treatmentDaniel C Javitt, Darryle Schoepp, Peter W Kalivas, et al.
Molecular Autism|January 6, 2022
Correction to: Visual attention and inhibitory control in children, teenagers and adults with autism without intellectual disability: results of oculomotor tasks from a 2-year longitudinal follow-up study (InFoR)Anouck Amestoy, Etienne Guillaud, Giulia Bucchioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Molecular Autism|November 14, 2021
Visual attention and inhibitory control in children, teenagers and adults with autism without intellectual disability: results of oculomotor tasks from a 2-year longitudinal follow-up study (InFoR)Anouck Amestoy, Etienne Guillaud, Giulia Bucchioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparisonNina R Schooler, Stephen R Marder, K N R Chengappa, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Autism and Developmental Disorders|April 13, 2020
Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional AnalysisMarta Del Valle Rubido, Eric Hollander, James T McCracken, et al.
JAMA Psychiatry|June 22, 2017
Placebo Response and Practice Effects in Schizophrenia Cognition TrialsRichard S E Keefe, Vicki G Davis, Philip D Harvey, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 8, 2012
Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteersMeret Martin-Facklam, Flavia Pizzagalli, Yun Zhou, et al.
Frontiers in Psychiatry|August 15, 2020
Social Anxiety in Children and Adolescents With Autism Spectrum Disorders Contribute to Impairments in Social Communication and Social MotivationKellen Briot, François Jean, Ali Jouni, et al.
Science Translational Medicine|September 30, 2011
Translating glutamate: from pathophysiology to treatmentDaniel C Javitt, Darryle Schoepp, Peter W Kalivas, et al.
Molecular Autism|January 6, 2022
Correction to: Visual attention and inhibitory control in children, teenagers and adults with autism without intellectual disability: results of oculomotor tasks from a 2-year longitudinal follow-up study (InFoR)Anouck Amestoy, Etienne Guillaud, Giulia Bucchioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Molecular Autism|November 14, 2021
Visual attention and inhibitory control in children, teenagers and adults with autism without intellectual disability: results of oculomotor tasks from a 2-year longitudinal follow-up study (InFoR)Anouck Amestoy, Etienne Guillaud, Giulia Bucchioni, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
The Journal of Clinical Psychiatry|April 2, 2016
Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparisonNina R Schooler, Stephen R Marder, K N R Chengappa, et al.
Pageof 8